Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4554-4561

  Song, Lynda ^a   Zlobin, Andrei ^a   Ghoshal, Pushpankur ^b   Zhang, Qing ^b   Houde, Christiane ^b   Weijzen, Sanne ^a   Jiang, Qun ^a   Nacheva, Elizabeth ^c   Yagan, Danny ^e   Davis, Eric ^f   Galiegue Zouitina, Sylvie ^g   Catovsky, Daniel ^d   Grogan, Thomas ^h   Fisher, Richard I ^a   Miele, Lucio ^a   Coignet, Lionel J ^a,b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e ILLINOIS MATHEMATICS AND SCIENCE ACADEMY   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g INSERM   (France)

^h UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN CBF1; RETINOIC ACID; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL TRANSFORMATION; CHROMOSOME 12Q; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE MAPPING; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA CELL LINE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SMRT GENE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 12; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE DELETION; GENE REARRANGEMENT; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE-BINDING PROTEIN; LYMPHOMA, NON-HODGKIN; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS);

EID: 21144435931     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4108     Document Type: Article

References (58)

1. Zutter MM, Korsmeyer SJ. The biology of low-grade malignant lymphomas. In: Canellos GP, Lister TA, Sklar JL, editors. The lymphomas. Philadelphia: Saunders; 1998. p. 337-52.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
3. Fisher RJ, Miller TP, Grogan TM. New REAL clinical entities. Cancer J Sci Am 1998;2:S5-12.
4. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470-80.
5. Matolcsy A. High-grade transformation of low-grade non-Hodgkin's lymphomas: mechanisms of tumor progression. Leuk Lymphoma 1999;34:251-9.
6. Kaleem Z, Wakoff AR, Smith RP, Hess JL. Elastic transformation of mantle cell lymphoma. Arch Pathol Lab Med 1996;20:577-80.
7. Rohatiner A, Lister TA. Diffuse low-grade B-cell lymphomas. In: Canellos GP, Lister TA, Sklar JL, editors. The lymphomas. Philadelphia: Saunders: 1998. p. 389-98.
8. Dyer MJ, Fischer P, Nacheva E, Labastide W, Karpas A. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;ll) chromosomal translocations. Blood 1990;75:709-14.
9. Dyer MJ, Nacheva E. Fischer P, Heward JM, Labastide W, Karpas A. A new human T-cell lymphoma cell line (Karpas 384) of the T-cell receptor γ/δ lineage with translocation t(7:14) (p13;q11.2). Leukemia 1993;7:1047-53.
10. Nacheva E, Dyer MJ, Fischer P, et al. C-myc translocations in de novo B-cell lineage acute leukemias with t(14;18) (cell lines Karpas 231 and 353). Blood 1993;82:231-40.
11. Nacheva E, Dyer MJ, Metivier C, et al. B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression. Blood 1994;84:3422-8.
12. Fischer P, Nacheva E, Mason DV, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2:5 translocation and rearrangement of the T-cell receptor β-chain gene. Blood 1988;72:234-40.
13. Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P. Surface IgM-κ specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 1968;28:1300-10.
14. Kluin-Nelemans HC, Limpens J, Meerabux J, et al. A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21). Leukemia 1991;5:221-4.
15. Guy K, Middleton PG, Bansal NS, Ross JA, Steel CM. Recurrent mutation of immunoglobulin and c-myc genes and differential expression of cell surface antigens occur in variant cell lines derived from a Burkitt lymphoma. Int J Cancer 1990;45:109-18.
16. Nagai M, Fujita M, Ohmori M, et al. Establishment of a novel human B-cell line (OZ) with t(14;18)(q32;q2I) and aberrant p53 expression was associated with the homozygous deletions of p15INK4B and p16INK4A genes. Hematol Oncol 1997;15:109-19.
17. Zani VJ, Asou N, Jadayel D, et al. Molecular cloning of complex chromosomal translocation t(8;14;12)-(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon. Blood 1996;87:3124-34.
18. Coignet LJ, Jafer O, Hamoudi R, Nacheva E, Catovsky D, Dyer MJ. Molecular characterisation of a new recurrent abnormality of chromosome 12q24 in lymphoid malignancies. Blood 1998;92:325a.
19. Ordentlich P, Downes M, Xie W, Genin A, Spinner NB, Evans RM. Unique forms of human and mouse nuclear receptor corepressor SMRT. Proc Natl Acad Sci USA 1999;96:2639-44.
20. Jiang Q, Galiegue-Zouitina S, Roumier C, Hildebrand MP, Thomas S, Coignet LJ. Genomic organization and refined mapping of the human silencing mediator of retinoid and thyroid hormone receptor (SMRT) gene on chromosome 12q24.3. Cytogenet Cell Genet 2001;92:217-20.
21. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996;272:408-11.
22. Yang WM, Inouye C, Zeng Y, Bearss D, Seto E. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc Natl Acad Sci U S A 1996;93:12845-50.
23. Ayer DE, Lawrence QA, Eisenman RN. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 1995;80:767-76.
24. Schreiber-Agus N, Chin L, Chen K, et al. An aminoterminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 1995;80:777-86.
25. Heinzel T, Lavinsky RM, Mullen TM, et al, A complex containing N-CoR, mSin3 and histone deacecylase mediates transcriptional repression. Nature 1997;387:43-8.
26. Nagy L, Kao HY, Chakravarti D, et al Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997;89:373-80.
27. Alland L, Muhle R, Hou H Jr, et al. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 1997;387:49-55.
28. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 1997;89:349-56.
29. Zhang Y, Iratni R, Erdjument-Bromage H, Tempst P, Reinberg D. Histone deacetylases and SAP18, a novel polypeptide are components of a human Sin3 complex. Cell 1997;89:357-64.
30. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377:454-7.
31. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;89:349-52.
32. Wolffe AP. Transcriptional control. Sinful repression. Nature 1997;387:16-7.
33. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
34. Hsieh JJ, Nofziger DE, Weinmaster G, Hayward SD. Epstein-Barr virus immortalization: Notch2 interacts with CBF1 and blocks differentiation. J Virol 1997;71:1938-45.
35. Shaffer AL. Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000;13:199-212.
36. Alizadeh A, Eisen MB. Davis RE, et al. Identification of molecularly and clinically distinct types of diffuse large B-cell lymphoma by gene expression profiling. Nature 2000;403:503-11.
37. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998;391:811-4.
38. Wong CW Privalsky ML. Transcriptional repression by the SMRT-mSin3 corepressor: multiple interactions, multiple mechanisms, and a potential role for TFIIB. Mol Cell Biol 1998;18:5500-10.
39. Joos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996;87:1571-8.
40. Hebert J, Jonveaux P, d'Agay MF, Berger R. Cytogenetic studies in patients with Richter's syndrome. Cancer Genet Cytogenet 1994;73:65-8.
41. Kao HY, Ordentlich P, Koyano-Nakagawa N, et al. Histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev 1998;12:2269-77.
42. Palmieri M, Sasso MP, Monese R, et al. Interaction of the nuclear protein CBF1 with the κB site of the IL-6 gene promoter. Nucleic Acids Res 1999;27:2785-91.
43. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Transcriptional roles of CCAAT/ enhancer binding protein-β, nuclear factor-κB, and C-promoter binding factor 1 in interleukin (IL)-1β-induced IL-6 synthesis by human rheumatoid fibroblast-like synoviocytes. J Biol Chem 1998;273:7620-7.
44. Fayad L, Cabanillas F. Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 1998;6:563-751.
45. Kato H, Kinoshita T, Suzuki S, et al. Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1998;2:71-9.
46. Kossakowska AE, Edwards DR, Prusinkiewicz C, et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metal-loproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999;94:2080-9.
47. Dhordain P, Albagli O, Lin RJ, et al. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A 1997;94:10762-7.
48. Oswald F, Liptay S, Adler G, Schmid RM. NF-κB2 is a putative target gene of activated Notch-1 via RBP-Jκ. Mol Cell Biol 1998;18:2077-88.
49. Sohn YC, Kwak E, Na Y Lee JW, Lee SK. Silencing mediator of retinoid and thyroid hormone receptors and activating signal cointegrator-2 as transcriptional coregulators of the orphan nuclear receptor Nur77. J Biol Chem 2001;276:43734-9.
50. Daniel S. Arvelo MB, Patel VI, et al. A20 protects endothelial cells from TNF, FAS and NK mediated cell death by inhibiting caspase 8 activation. Blood 2004; prepublished online DOI 10.1182/blood-2003-02-0635.
51. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
52. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 1999;274:22532-8.
53. Lasorella A, Iavarone A, Israel MA. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol 1996;16:2570-8.
54. Iavarone A, Garg P, Lasorella A, Hsu J, Israel MA. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev 1994;8:1270-84.
55. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte- endothelial cell primary adhesion pathway. J Exp Med 1996;183:1119-30.
56. Pals ST, Horst E, Ossekoppele GJ, Figdor CG, Scheper RJ, Meijer CJ. Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood 1989;73:885-8.
57. Shinagawa T, Dong HD, Xu M, et al. The sno gene, which encodes a component of the histone deacetylase complex, acts as a tumor suppressor in mice. EMBO J 2000;19:2280-91.
58. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 2003;100:15077-82.